ReviewBritish journal of pharmacology2020
Hyperlipidaemia and cardioprotection: Animal models for translational studies.
Review in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction.European heart journal · 2026Article
- Preclinical Evaluation of Berry Extracts as a Nutritional Intervention to Alleviate Myocardial Ischemia-Reperfusion Injury and Atherosclerosis Development.Phytotherapy research : PTR · 2026Article
- Article
- The Peels of Fruits and Vegetables: An Increasingly Recognized Source of Bioactive Compounds for Biomedical Applications.Plants (Basel, Switzerland) · 2026Article
- Maternal high-fat diet and its multigenerational impact on hypertension and metabolic alterations in Wistar rat offspring.Journal of molecular histology · 2026Article
- An activator of phosphatidylinositol 3-kinase alpha restores cardioprotection from ischaemia/reperfusion injury in mice with coronary atherosclerosis or insulin resistance.Cardiovascular research · 2025Article
- Current status and challenges of multi-omics research using animal models of atherosclerosis.Journal of molecular and cellular cardiology plus · 2025Review
- Early-Life Prevention of Cardiovascular-Kidney-Metabolic Syndrome: The DOHaD Perspective on Resveratrol and Short-Chain Fatty Acids.Antioxidants (Basel, Switzerland) · 2025Review
- Preventive, ameliorative, and therapeutic effects of steamed mature silkworms on metabolic disorders caused by loss of apolipoprotein E.NPJ science of food · 2025Article
- Toxicological evaluation and preliminary phytochemical characterisation of a NigerianIranian journal of basic medical sciences · 2025Article
- Harnessing the power of bioprinting for the development of next-generation models of thrombosis.Bioactive materials · 2024Review
- Review
- Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review).International journal of molecular medicine · 2024Review
- Antiplatelet Effects of a Combination of Sappan Wood (Advances in pharmacological and pharmaceutical sciences · 2024Article
- Whole blood gene expression analysis of spontaneous hypertriglyceridemia in dogs suggests an underlying pro-thrombotic process.PloS one · 2024Article
- Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.Cardiovascular drugs and therapy · 2023Review
- Fatty Acid-Binding Proteins Identification during the Evolution of Metabolic Syndrome: A Raman Spectroscopy-Based Approach.Molecules (Basel, Switzerland) · 2023Article
- Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection.Redox biology · 2023Review
- High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study.Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 7 countries.
Funding
Abstract
Hyperlipidaemia is a well-established risk factor for cardiovascular diseases and therefore, many animal model have been developed to mimic the human abnormal elevation of blood lipid levels. In parallel, extensive research for the alleviation of ischaemia/reperfusion injury has revealed that hyperlipidaemia is a major co-morbidity that attenuates the cardioprotective effect of conditioning strategies (preconditioning, postconditioning and remote conditioning) and that of pharmacological interventions by interfering with cardioprotective signalling pathways. In the present review article, we summarize the existing data on animal models of hypercholesterolaemia (total, low density and HDL abnormalities) and hypertriglyceridaemia used in ischaemia/reperfusion injury and protection from it. We also provide recommendations on preclinical animal models to be used for translations of the cardioprotective strategies into clinical practice. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.